Atossa Therapeutics マネジメント

マネジメント基準チェック /34

Atossa Therapeuticsの CEO はSteve Quayで、 Apr2009年に任命され、の在任期間は 15.58年です。の年間総報酬は$ 2.36Mで、 30%給与と70%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.002%を直接所有しており、その価値は$ 3.19K 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と12.8年です。

主要情報

Steve Quay

最高経営責任者

US$2.4m

報酬総額

CEO給与比率	30.0%
CEO在任期間	15.6yrs
CEOの所有権	0.002%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	12.8yrs

経営陣の近況

Recent updates

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Jan 09

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Oct 11

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Sep 25

Atossa Therapeutics GAAP EPS of -$0.05

Aug 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

CEO報酬分析

Atossa Therapeutics の収益と比較して、Steve Quay の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$2m	US$706k	-US$30m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$3m	US$706k	-US$27m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$6m	US$659k	-US$21m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$26m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$3m	US$601k	-US$22m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$6m	US$601k	-US$17m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$25m
Dec 31 2018	US$2m	US$582k	-US$23m
Sep 30 2018	n/a	n/a	-US$23m
Jun 30 2018	n/a	n/a	-US$22m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$1m	US$520k	-US$11m

報酬と市場: Steveの総報酬 ($USD 2.36M ) は、 US市場 ($USD 1.47M ) の同規模の企業の平均を上回っています。

報酬と収益: Steveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Steve Quay (73 yo)

15.6yrs

在職期間

US$2,356,220

報酬

Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Steven Quay	Chairman	15.6yrs	US$2.36m	0.0021% $ 3.2k
Heather Rees	Chief Financial Officer & Principal Accounting Officer	3.8yrs	US$687.46k	0% $ 0
Delly Behen	Senior Vice President of Administration & HR	10.3yrs	データなし	データなし
Eric Van Zanten	Vice President of Investor & Public Relations	2.8yrs	データなし	データなし
Richard Graydon	Interim Chief Medical Officer	2.1yrs	データなし	データなし

3.8yrs

平均在職期間

経験豊富な経営陣: ATOSの経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Steven Quay	Chairman	15.6yrs	US$2.36m	0.0021% $ 3.2k
Richard Steinhart	Independent Director	10.7yrs	US$146.17k	0% $ 0
H. Remmel	Independent Director	12.8yrs	US$144.92k	0.00020% $ 301.9
Shu-Chih Chen	Director	15.6yrs	US$116.17k	0.018% $ 26.7k
Stephen Galli	Independent Director	13.3yrs	US$144.92k	0.000080% $ 120.8
Jonathan Finn	Independent Director	less than a year	US$93.98k	0.020% $ 30.0k
Tessa Cigler	Independent Director	less than a year	データなし	データなし

12.8yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: ATOSの取締役会は経験豊富で経験豊富です ( 12.8年の平均在任期間)。

Atossa Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Recent updates

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target increased by 7.7% to US$5.83

New major risk - Revenue and earnings growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

New minor risk - Share price stability

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

New minor risk - Share price stability

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Price target decreased by 7.5% to US$4.63

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Price target decreased to US$5.00

Price target decreased to US$5.00

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics GAAP EPS of -$0.05

Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Insufficient new directors

Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants

Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022

No longer forecast to breakeven

Price target decreased to US$6.38

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Forecast to breakeven in 2024

マネジメント基準チェック /34